Kevin Dai is a Managing Director at Vivo Capital. He has a background in clinical oncology pharmacy and equity research.
At firms with a similar stage, sector and check size.




One email when Kevin's firm raises a fund, adds a partner or shows new activity.

Raising a pre-seed or seed round? We write $1M to $5M first checks and help founders with distribution. A partner reads every deck.
Send your deckKevin Dai is a Managing Director at Vivo Capital. He has a background in clinical oncology pharmacy and equity research.
Vivo Capital has not reported a check size. It invests at series a, series b.
Email [email protected], the firm's inbox for founders, and name Kevin in the subject. A warm intro from a founder Vivo Capital backed works better.
Merck & Co.; Clinical Oncology Pharmacy Specialist at Memorial Sloan Kettering Cancer Center; equity research associate at Canaccord Genuity.
Last updated 2026-10-15. Is this you? Ask for a correction.